Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of HTL0018318 in healthy adults
NL-OMON24000Active, not recruiting
- Sponsor
- Heptares Therapeutics
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of HTL0018318 in Alzheimer's disease (AD) and Dementia, sponsored by Heptares Therapeutics. Started Mar 2016; status: active, not recruiting.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON24000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24000.